RedHill enters into agreement to promote GERD PPI — 4 key notes

RedHill Biopharma entered into a commercialization agreement with ParaPRO to promote RedHill’s Esomeprazole Strontium Delayed-Release capsules.

Advertisement

Here’s what you should know:

1. The capsules are proton pump inhibitors used to treat gastroesophageal reflux disease. They also reduce the risk of duodenal ulcer nonsteroidal anti-inflammatory drug-associated gastric ulcers.

2. The product can be marketed to gastroenterologists in select U.S. areas.

3. Redhill believes promotion will begin in the next few weeks.

4. This is RedHill’s third U.S.-based product.

More articles on gastroenterology: 
GI center to know: Gateway Gastroenterology
United Healthcare honors Dr. Darrien Gaston of Metropolitan Gastroenterology Consultants — 3 key notes
Providence Medical Group adds a new physician & more: 4 GI practices in the news

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.